Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NouvSoma002-01
- Development stage
- Phase 1
- Lead developer
- iRegene Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
NouvSoma002-01 is an investigational exosome-based therapy composed of extracellular vesicles (EVs) derived from human induced pluripotent stem cells (iPSCs). Developed by iRegene Therapeutics, it is specifically being evaluated for the treatment of Moyamoya disease, a progressive cerebrovascular disorder characterized by the narrowing of internal carotid arteries. The therapy is designed to leverage the regenerative and anti-inflammatory potential of iPSC-derived EVs to stimulate angiogenesis (vascular regeneration) and facilitate the establishment of intracranial and extracranial collateral circulation. In clinical trials, NouvSoma002-01 is administered locally in combination with surgical procedures, such as temporal muscle flap application, to enhance revascularization and improve neurological outcomes by inhibiting the release of pro-inflammatory factors from glial cells.
- Other names
- iPSC-derived extracellular vesiclesiPSC-EVsinduced pluripotent stem cell-derived extracellular vesiclesiPSC-derived exosomes
Beyond the preview
Go deeper on NouvSoma002-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NouvSoma002-01.